PPARγ Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study

Activating synthetic ligands for peroxisome proliferator-activated receptor gamma (PPARγ), such as pioglitazone, are commonly used to treat persons with diabetes mellitus with improvement of insulin resistance. Several reports have clearly demonstrated that PPARγ ligands could inhibit colorectal can...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Hirokazu, Hosono, Kunihiro, Uchiyama, Takashi, Sugiyama, Michiko, Sakai, Eiji, Endo, Hiroki, Maeda, Shin, Schaefer, Katherine L., Nakagama, Hitoshi, Nakajima, Atsushi
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2929500/
https://www.ncbi.nlm.nih.gov/pubmed/20814432
http://dx.doi.org/10.1155/2010/257835

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2929500/
https://www.ncbi.nlm.nih.gov/pubmed/20814432
http://dx.doi.org/10.1155/2010/257835

Ejemplares similares